February 2010
Worldwide Biotech;Feb2010, Vol. 22 Issue 2, p1
Trade Publication
This article announces the discovery and experimental validation by Compugen Ltd. of CGEN-671, a new drug target for multiple epithelial tumors. The company's Monoclonal Antibody Targets Discovery Platform was used to determine the potential application of CGEN-671 as a drug target. Particular focus is given to the results of CGEN-671's experimental and immunohistochemistry studies. Comments from Compugen President Anat Cohen-Dayag regarding the validation of CGEN-671 are presented.


Related Articles

  • Compugen Ltd Reports 1st Qtr 2012 Financial Results.  // Biomedical Market Newsletter;5/5/2012, Vol. 21, p1 

    The article reports on the release of financial results of the first quarter ending March 31, 2012 by Compugen Ltd. Anat Cohen-Dayag, president and chief executive office of Compugen, states that this corporate profit has been achieved due to its new facility operations in South San Francisco...

  • PEOPLE IN PLACES.  // Diagnostics & Imaging Week;6/11/2009, Vol. 12 Issue 23, p12 

    The article announces the appointment of Anat Cohen-Dayag and Martin Gerstel as co-chief executive officers (CEOs) of Compugen.

  • Compugen announces discovery of new cancer biomarker candidate.  // PharmaWatch: Cancer;Mar2009, Vol. 8 Issue 3, p13 

    The article reports on the discovery of CGEN-327, a molecular biomarker candidate for ovarian cancer diagnosis, by young drug and diagnostic discovery company Compugen Ltd. It offers updates on the company's business developments related to the product candidate. Compugen research and...

  • OTHER NEWS TO NOTE.  // BioWorld Today;6/3/2009, Vol. 20 Issue 105, p2 

    This section offers news briefs concerning biotechnology industry. Ancora Pharmaceuticals Inc. has been awarded a grant from the U.S. National Institutes of Health (NIH) to study whether its carbohydrate-based vaccine candidate is capable of preventing severe malaria anemia. China's State Food...

  • The influence of thermo-chemotherapy on bladder tumours: an immunohistochemical analysis. van der Heijden, Antoine G.; Hulsbergen- Van de Kaa, Christina A.; Witjes, J. Alfred // World Journal of Urology;Jun2007, Vol. 25 Issue 3, p303 

    To study the influence of microwave induced thermo-chemotherapy on high-grade urothelial cell carcinomas. Five groups of each three patients were formed of whom initial biopsies and cystectomy samples were collected. Patients were treated 2 days prior to cystectomy with mitomycin-C (group 1),...

  • Clinical importance of B7-H3 expression in human pancreatic cancer. Yamato, I.; Sho, M.; Nomi, T.; Akahori, T.; Shimada, K.; Hotta, K.; Kanehiro, H.; Konishi, N.; Yagita, H.; Nakajima, Y. // British Journal of Cancer;11/17/2009, Vol. 101 Issue 10, p1709 

    Background:B7-H3 is a new member of the B7 ligand family and regulates T-cell responses in various conditions. However, the role of B7-H3 in tumour immunity is largely unknown. The purpose of this study was to evaluate the clinical significance of B7-H3 expression in human pancreatic cancer and...

  • Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors. Devarakonda, Charan V.; Kita, Daniel; Phoenix, Kathryn N.; Claffey, Kevin P. // BMC Cancer;9/3/2015, Vol. 15 Issue 1, p1 

    Background: Monoclonal antibodies have been used to effectively treat various tumors. We previously established a unique strategy to identify tumor specific antibodies by capturing B-cell response against breast tumor antigens from patient-derived sentinel lymph nodes. Initial application of...

  • Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting. Fan, Li; Campagnoli, Susanna; Hong Wu; Grandi, Alberto; Parri, Matteo; De Camilli, Elisa; Grandi, Guido; Viale, Giuseppe; Pileri, Piero; Grifantini, Renata; Song, Chaojun; Jin, Boquan // Journal of Experimental & Clinical Cancer Research (17569966);12/1/2015, Vol. 34, p1 

    Background: Herein, we demonstrated the use of a newly generated anti FAT1 antibody (clone mAB198.3) for intracellular delivery of anionic gold NPs, to form active targeting Au nanoparticles with high payload characteristics. Methods: In vitro characterizations were determined by DLS, confocal...

  • CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Selenko, N; Majdic, O; Draxler, S; Berer, A; Jäger, U; Knapp, W; Stöckl, J; Maidic, O; Draxier, S // Leukemia (08876924);Oct2001, Vol. 15 Issue 10, p1619 

    C2B8 (Rituximab, MabThera) is a chimeric mouse/human monoclonal antibody (mAb) directed against the human B cell-restricted cell surface antigen CD20 which is used as an alternative medication in the treatment of B cell non-Hodgkin lymphomas (NHL). Treatment of CD20+ B cells with C2B8 triggers...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics